



## LAXMI DENTAL LIMITED

formerly known as Laxmi Dental Export Private Limited

**Registered Office:** 103, Akruti Arcade, Opposite A H Wadia High School, Near Azad Nagar Metro Station, Andheri (West), Mumbai –400058.

**Tel:** 022 61437991 | **Email:** info@laxmidentallimited.com | **Website:** www.laxmidentallimited.com

**CIN No:** U51507MH2004PLC147394 | **GST No:** 27AABCL0001A1ZL

**Date:** February 13, 2025

**Listing Department**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001  
**BSE Scrip Code: 544339**

**Listing & Compliance Department**  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/1, "G" Block  
Bandra-Kurla Complex  
Bandra (E), Mumbai – 400 051  
**Symbol: LAXMIDENTL**

Dear Sir(s)/Madam(s),

**Subject: Outcome of Board Meeting - Pursuant to Regulation 33 and 30 of the SEBI (LODR), Regulations, 2015:**

This is to inform you that the Board of Directors, at its meeting held on Thursday, February 13, 2025 inter-alia has considered and approved the following:

1. The Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and nine months ended December 31, 2024 (Q3/9M-FY25) and took note of the Limited Review Reports issued by the Statutory Auditors on the Unaudited Consolidated and Standalone Financial Result of the Company for the quarter and nine months ended December 31, 2024. A copy of the said Unaudited Consolidated and Standalone Financial Results of the Company together with the Limited Review Reports thereon is enclosed herewith.
2. Granted in- principal approval for providing an unsecured loan to Signature Smiles Dental Clinic Pvt. Ltd, a subsidiary of the Company up to Rs. 2,00,00,000/- (Rupees Two Crores Only) in one or more tranches. The Company shall update the exchange and make necessary disclosure as per regulation 30 of listing regulation at the time of execution of definitive agreements and actual grant of loan.
3. Granted in- principal approval in- principal approval for investment in Bizdent Devices Private Limited, a wholly owned Subsidiary of the Company up to Rs. 20,00,00,000/- (Twenty Crores Only) in one or more tranches. The Company shall update the exchange and make necessary disclosure as per regulation 30 of listing regulation at the time of execution of definitive agreements and actual investments.

The meeting commenced at 03:00 P.M.

The meeting was concluded at 09:15 P.M.

Kindly take the same on your record.

**For Laxmi Dental Limited**  
**(Formerly Known as Laxmi Dental Export Private Limited)**

---

**Nupur Joshi**  
**Company Secretary and Compliance Officer**  
**Membership Number: A43768**

Encl.: As above.

# MSKA & Associates

Chartered Accountants

HO  
602, Floor 6, Raheja Titanium,  
Western Express Highway, Geetanjali  
Railway Colony, Ram Nagar,  
Goregaon (E), Mumbai 400063, INDIA  
Tel: +91 22 6974 0200

Independent Auditor's Review Report on Standalone unaudited financial results of Laxmi Dental Limited (Formerly known as Laxmi Dental Export Private Limited) for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Laxmi Dental Limited (Formerly known as Laxmi Dental Export Private Limited)

1. We have reviewed the accompanying statement of standalone unaudited financial results of Laxmi Dental Limited (Formerly known as Laxmi Dental Export Private Limited) (hereinafter referred to as 'the Company') for the quarter ended December 31, 2024 and the year to-date results for the period from April 1, 2024 to December 31, 2024 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognized accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement includes results for the quarter ended September 30, 2024, December 31, 2023 and the year to-date results for the period from April 1, 2023 to December 31, 2023, that have been approved by the Board of Directors and have not been subjected to review by us or by another auditor. Our conclusion is not modified in respect of the above matter.

For M S K A & Associates  
Chartered Accountants  
ICAI Firm Registration No.105047W



Nitin Tiwari  
Partner  
Membership No.: 118894  
UDIN: 25118894BMKXRI6416



Place: Mumbai  
Date: February 13, 2025

# Laxmi Dental Limited (Formerly known as Laxmi Dental Export Private Limited)

Corporate Identity Number: U51507MH2004PLC147394

Registered Office :- 103, Akruiti Arcade, J P Road, Opposite A H Wadia School, Near Azad Nagar Metro Station, Andheri (West), Mumbai, Maharashtra 400058  
Tel: 022-61437991 Website: www.laxmidentallimited.com, Email ID - co.sec@laxmidentallimited.com

## Statement of Standalone Unaudited Financial Results for the Quarter ended and Nine months ended December 31, 2024

(Rs. in millions except earnings per share data)

Particulars	Quarter ended			Nine months ended		Year Ended
	31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	31-Mar-24
	(Unaudited)	(Unaudited) Refer Note 4	(Unaudited) Refer Note 4	Unaudited	(Unaudited) Refer Note 4	Audited
<b>I. Income</b>						
<b>a) Revenue from operations</b>						
i. Sales	427.55	415.76	344.99	1,271.24	988.64	1,378.78
ii. Other Operating Revenue	5.85	4.07	4.16	14.33	13.77	15.10
<b>b) Other Income</b>	8.67	7.68	11.13	24.42	37.91	52.94
<b>Total Income</b>	<b>442.07</b>	<b>427.51</b>	<b>360.28</b>	<b>1,309.99</b>	<b>1,040.32</b>	<b>1,446.82</b>
<b>II. Expenses</b>						
<b>a) Cost of material consumed</b>	116.06	115.01	134.29	370.51	349.62	398.60
<b>b) Purchase of stock-in-trade</b>	13.44	26.81	13.42	55.45	63.81	118.79
<b>c) Change in inventories of finished goods, work in progress and stock in trade</b>	15.87	13.51	(10.56)	19.95	(44.40)	(19.98)
<b>d) Employee benefits expenses</b>	154.54	144.10	135.37	419.66	389.47	523.00
<b>e) Finance costs</b>	10.08	8.58	10.97	29.48	30.30	42.17
<b>f) Depreciation and amortization expenses</b>	26.70	21.30	24.92	69.88	67.82	91.21
<b>g) Other expenses</b>	77.69	72.81	65.54	231.73	193.08	260.80
<b>Total Expenses</b>	<b>414.38</b>	<b>402.12</b>	<b>373.95</b>	<b>1,196.66</b>	<b>1,049.70</b>	<b>1,414.59</b>
<b>III. Profit/ (Loss) before Exceptional items and tax</b>	27.69	25.39	(13.67)	113.33	(9.38)	32.23
<b>IV. Exceptional items (net of tax) (Refer Note 8)</b>	-	-	-	66.17	-	-
<b>V. Profit/ (Loss) before tax</b>	27.69	25.39	(13.67)	179.50	(9.38)	32.23
<b>VI. Tax Expense:</b>						
a) Current tax	-	-	-	-	-	7.33
b) Adjustment of tax relating to earlier periods	(1.59)	-	-	(1.59)	-	-
c) Deferred tax	8.89	8.99	(11.78)	29.36	(109.90)	(111.53)
<b>Total Tax Expenses</b>	<b>7.30</b>	<b>8.99</b>	<b>(11.78)</b>	<b>27.77</b>	<b>(109.90)</b>	<b>(104.20)</b>
<b>VII. Share in Profit of Joint Venture</b>	11.75	21.56	19.52	64.26	67.03	90.67
<b>VIII. Profit for the period/ year</b>	<b>32.14</b>	<b>37.96</b>	<b>17.63</b>	<b>215.99</b>	<b>167.55</b>	<b>227.10</b>
<b>IX. Other comprehensive income:</b>						
Items that will not be reclassified to profit or loss						
Remeasurement of net defined benefit liabilities/ assets	0.65	(2.23)	1.33	(1.58)	4.00	5.33
Income tax effect on above	(0.19)	0.65	(0.37)	0.46	(1.11)	(1.48)
<b>Other comprehensive income/(Loss) for the period/year</b>	<b>0.46</b>	<b>(1.58)</b>	<b>0.96</b>	<b>(1.12)</b>	<b>2.89</b>	<b>3.85</b>
<b>X. Total comprehensive income for the period/ year</b>	<b>32.60</b>	<b>36.38</b>	<b>18.59</b>	<b>214.87</b>	<b>170.44</b>	<b>230.95</b>
<b>XI. Paid up Equity Share Capital (face value ₹2 each fully paid) (Refer Note 9)</b>	103.48	55.63	3.08	103.48	3.08	3.08
<b>XII. Other Equity</b>						628.70
<b>XIII. Earnings Per Equity Share (Face Value of Rs. each)* (Refer Note 9)</b>						
a) Basic (Rs.)	0.59	0.73	0.34	4.12	3.24	4.40
b) Diluted (Rs.)	0.59	0.73	0.34	4.12	3.24	4.40

\* EPS is not annualized for quarter and nine months ended December 31, 2024, quarter ended September 30, 2024 and quarter and nine months ended December 31, 2023.





Laxmi Dental Limited (Formerly known as Laxmi Dental Export Private Limited)

Notes to the Statement of Standalone Financial Results for the Quarter and Year Ended December 31, 2024:

1. The unaudited standalone financial results for the quarter and nine months ended December 31, 2024 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 13, 2025. The Statutory Auditors of the Company have carried out limited review (for the quarter ended December 31, 2024 and year to date ended December 31, 2024) on the above results in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation'), as amended and expressed an unmodified conclusion.
2. The unaudited standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulation.
3. As per Ind AS 108 on "Segment Reporting", segment information has been provided under the notes to Statement of consolidated unaudited financial results.
4. The figures of the corresponding quarter ended and nine month period ended December 31, 2023 and the quarter ended September 30, 2024 are presented based on the information complied by the management in accordance with IND AS and have not been subject to review or audit by the statutory auditors. However, the management have prepared the results for the said periods by applying consistent accounting policies. The requirement of submission of quarterly unaudited standalone financial results is applicable on the listing of the equity shares of the company for the quarter ended December 31, 2024. Accordingly, these financial results have been prepared for the first time in compliance with the regulations.
5. The figures for the year ended March 31, 2024 have been extracted form the general purpose Standalone financials statement of the company which were audited by the Statutory Auditors of the company.
6. During the quarter, the Board of Directors and Shareholders of the Company has approved the Employee Stock Option Plan 2024 ("ESOP 2024") for the employees of the Company and its subsidiary companies comprising of equity shares of the Company, not exceeding 5,00,000 equity shares of face value of Rs. 2/- each. The company has granted 351, 672 equity shares of face value of Rs. 2/- each on December 14, 2024 to its eligible employees.
7. During the quarter ended December 31, 2024, the Company has converted the 0.0001% Compulsorily Convertible Preference Shares (CCPS) aggregating to 290,597 preference shares of par value of Rs. 400 each were converted to 23,930,663 Equity Shares of Rs. 2 each.
8. On May 07, 2024, the Company sold one of its Investment properties at the sale consideration of Rs. 101 million. The book value of the aforesaid Property as on the date of sale was Rs. 7.10 million. The Company accounted for difference between the sale consideration and book value as gain on sale of Investment property Rs. 66.17 million (net of tax Rs. 27.73 million) as an exceptional gain.
9. During the period ended December 31, 2024, the Company split its 309,060 equity shares of face value of Rs.10 each to 1,545,300 Equity Shares of face value of Rs.2 each. Further, on approval of the Board of Directors and Shareholders, the company issued 26,270,100 bonus shares (17:1) face value of Rs. 2 each, by capitalizing the free reserves. Basic and Diluted EPS disclosed after considering effect of bonus and split equity shares issued.
10. Subsequent to the quarter and nine month ended December 31, 2024, the Company has completed an Initial Public Offer of 16,309,766 equity shares of face value of Rs. 2/- each comprising of (i) fresh issue of 3,224,299 equity shares at an issue price of Rs. 428 per equity share aggregating to Rs. 1,380 million, and (ii) an offer for sale of 13,085,467 equity shares at an issue price of Rs. 428 per equity share aggregating to Rs. 5,600.58 million and listed on both Bombay Stock Exchange Limited (BSE) and National Stock Exchange (NSE) on January 20, 2025.
11. The above unaudited standalone financial results of the Company are available on the Company's website ([www.laxmidentallimited.com](http://www.laxmidentallimited.com)) and stock exchanges websites, BSE([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)), where the shares of the Company are listed.



  
Sameer Merchant  
CEO & Managing Director  
DIN: 00679893

Date : February 13, 2025  
Place : Mumbai  
[www.laxmidentallimited.com](http://www.laxmidentallimited.com)



Independent Auditor's Review Report on consolidated unaudited financial results of Laxmi Dental Limited (Formerly known as Laxmi Dental Export Private Limited) for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Laxmi Dental Limited (Formerly known as Laxmi Dental Export Private Limited)

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Laxmi Dental Limited (Formerly known as Laxmi Dental Export Private Limited) (hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') and its jointly controlled entity for the quarter ended December 31, 2024 and the year to-date results for the period from April 1, 2024 to December 31, 2024 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Bizdent Devices Private Limited	Wholly Owned Subsidiary of Holding Company.
2	Signature Smile Dental Clinic Private Limited	Subsidiary of Holding Company (88.88%)
3	Rich Smile Design LLP	Subsidiary of Holding Company (66.00%)
4	Laxmi Dental Lab USA INC.	Wholly owned Subsidiary (55.56% owned by Holding Company and 44.44% owned by Bizdent Devices Private Limited)
5	Diverse Dental Lab LLC	Subsidiary of Laxmi Dental Lab USA INC. (85.00%)
6	Illusion Dental Lab USA Inc.	Wholly Owned Subsidiary of Laxmi Dental Lab USA INC.
7	KIDS-E-Dental LLP	Joint venture of Holding Company (60.00%)





# MSKA & Associates

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of five subsidiaries included in the Statement, whose financial information, before giving effect to the consolidation adjustments, reflects total revenues of Rs. 126.28 million and Rs. 344.86 million, total net profit after tax of Rs. 9.31 million and Rs. 31.15 million and total comprehensive income of Rs. 8.97 million and Rs. 24.36 million for the quarter ended December 31, 2024 and for the period from April 01, 2024 to December 31, 2024 respectively, as considered in the Statement. The interim financial information of the subsidiaries have been reviewed by the other auditor whose reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of the subsidiaries are based solely on the reports of such other auditor and the procedures performed by us as stated in paragraph 3 above.  
  
Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditor.
7. The Statement includes results for the quarter ended September 30, 2024, December 31, 2023 and the year to-date results for the period from April 1, 2023 to December 31, 2023, that have been approved by the Board of Directors, and have not been subjected to review by us or by another auditor. Our conclusion is not modified in respect of the above matter.

For M S K A & Associates  
Chartered Accountants  
ICAI Firm Registration No.105047W



Nitin Tiwari  
Partner  
Membership No.: 118894  
UDIN: 25118894BMKXRJ7127



Place: Mumbai  
Date: February 13, 2025

Laxmi Dental Limited (Formerly known as Laxmi Dental Export Private Limited)

Corporate Identity Number: US1507MH2004PLC147394


Registered Office - 103, Akruvi Arcade, J P Road, Opposite A H Wadia School, Near Azad Nagar Metro Station, Andheri (West), Mumbai, Maharashtra 400058  
Tel: 022 61437991 Website: www.laxmidentallimited.com Email Id - co.sec@laxmidentallimited.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2024

(Rs. in millions except earnings per share data)

Particulars	Quarter ended			Nine months ended		
	31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	Year ended 31-Mar-24
	Unaudited	(Unaudited) Refer Note 3	(Unaudited) Refer Note 3	Unaudited	(Unaudited) Refer Note 3	Audited
<b>I. Income</b>						
a) Revenue from operations						
i. Sales	604.65	565.73	472.86	1,761.44	1,368.86	1,914.50
ii. Other Operating Revenue	11.95	5.46	5.00	22.96	16.22	21.05
b) Other Income	5.86	7.27	2.00	17.07	14.04	17.09
<b>Total Income</b>	<b>622.46</b>	<b>578.46</b>	<b>479.86</b>	<b>1,801.47</b>	<b>1,399.12</b>	<b>1,952.64</b>
<b>II. Expenses</b>						
a) Cost of material consumed	68.83	131.54	136.97	331.22	371.67	464.18
b) Purchase of stock-in-trade	77.30	4.02	4.77	102.07	33.73	38.35
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	14.81	3.10	(8.93)	10.20	(43.78)	(17.64)
d) Employee benefits expenses	217.62	205.42	182.21	601.01	523.51	715.11
e) Finance costs	15.35	11.75	13.33	41.33	35.51	49.54
f) Depreciation and amortization expenses	39.53	34.01	32.46	107.21	86.78	119.36
g) Other expenses	141.90	139.85	123.55	416.40	378.88	497.65
<b>Total Expenses</b>	<b>575.34</b>	<b>529.69</b>	<b>484.36</b>	<b>1,609.44</b>	<b>1,386.30</b>	<b>1,866.55</b>
<b>III. Profit/ (Loss) before Exceptional items and tax</b>	<b>47.12</b>	<b>48.77</b>	<b>(4.50)</b>	<b>192.03</b>	<b>12.82</b>	<b>86.09</b>
IV. Exceptional items (net of tax) (Refer Note 8)	-	-	-	66.17	-	(0.85)
<b>V. Profit/ (Loss) before tax for the period/ year</b>	<b>47.12</b>	<b>48.77</b>	<b>(4.50)</b>	<b>258.20</b>	<b>12.82</b>	<b>85.24</b>
<b>VI. Tax Expense:</b>						
a) Current tax	3.35	3.63	(2.22)	13.07	5.58	17.85
b) Adjustment of tax relating to earlier	(0.02)	(0.25)	-	(0.53)	-	(0.14)
c) Deferred tax	7.37	8.00	(11.87)	27.22	(110.57)	(111.88)
<b>Total Tax Expenses</b>	<b>10.70</b>	<b>11.38</b>	<b>(14.09)</b>	<b>39.76</b>	<b>(104.99)</b>	<b>(94.17)</b>
<b>VII. Profit after tax for the period/ year</b>	<b>36.42</b>	<b>37.39</b>	<b>9.59</b>	<b>218.44</b>	<b>117.81</b>	<b>179.41</b>
<b>VIII. Share in Profit of Joint Venture</b>	<b>11.75</b>	<b>21.56</b>	<b>19.52</b>	<b>64.26</b>	<b>67.03</b>	<b>88.88</b>
<b>IX. Profit for the period/ year from continuing operations</b>	<b>48.17</b>	<b>58.95</b>	<b>29.11</b>	<b>282.70</b>	<b>184.84</b>	<b>268.29</b>
X. Loss Before Tax from Discontinued Operations	-	-	(5.61)	(8.09)	(9.59)	(16.00)
XI. Tax Income from Discontinuing Operations	-	-	-	1.00	-	-
<b>XII. Loss after tax from discontinuing operations</b>	<b>-</b>	<b>-</b>	<b>(5.61)</b>	<b>(7.09)</b>	<b>(9.59)</b>	<b>(16.00)</b>
<b>XIII. Profit for the period/ year</b>	<b>48.17</b>	<b>58.95</b>	<b>23.50</b>	<b>275.61</b>	<b>175.25</b>	<b>252.29</b>
<b>XIV. Other comprehensive income:</b>						
<b>Other Comprehensive Income from continuing Operations</b>						
<b>Items that will not be reclassified to profit or loss</b>						
Remeasurement gain of net defined benefit plan	1.08	(1.82)	0.31	(0.31)	0.94	1.14
Income tax effect on above	(0.27)	0.58	(0.19)	0.23	(0.58)	(0.78)
<b>Items that will be reclassified to Profit or Loss</b>						
Foreign currency translation difference of foreign operations	-	-	-	-	-	(0.96)
Income tax effect on above	-	-	-	-	-	-
<b>Other Comprehensive Income from Discontinuing Operations</b>						
<b>Items that will be reclassified to Profit or Loss</b>						
Foreign Currency Translation difference of Foreign Operations	(0.32)	2.12	(1.41)	0.34	(2.65)	(0.80)
Income Tax effect on above	-	-	-	-	-	-
<b>XV. Other Comprehensive Income/(loss) for the period/ year, net of tax</b>	<b>0.49</b>	<b>0.88</b>	<b>(1.29)</b>	<b>0.26</b>	<b>(2.29)</b>	<b>(1.40)</b>
<b>XVI. Profit for the period/ year attributable to:</b>						
Owners of the Parent	48.66	59.83	22.21	275.87	172.96	250.89
Non-Controlling Interests	0.17	0.05	0.71	0.70	2.52	4.51
<b>Total</b>	<b>48.17</b>	<b>58.95</b>	<b>23.50</b>	<b>275.61</b>	<b>175.25</b>	<b>252.29</b>
<b>XVII. Other Comprehensive Income/(Loss) for the period/ year attributable to:</b>						
Owners of the Parent	0.49	0.88	(1.17)	0.26	(2.04)	(1.06)
Non-Controlling Interests	(0.00)	(0.00)	(0.12)	(0.00)	(0.25)	(0.34)
<b>Total</b>	<b>0.49</b>	<b>0.88</b>	<b>(1.29)</b>	<b>0.26</b>	<b>(2.29)</b>	<b>(1.40)</b>
<b>XVIII. Total Comprehensive Income for the period/ year attributable to:</b>						
Owners of the Parent	48.49	59.78	21.62	275.17	170.69	246.73
Non-Controlling Interests	0.17	0.05	0.59	0.70	2.27	4.16
<b>Total</b>	<b>48.66</b>	<b>59.83</b>	<b>22.21</b>	<b>275.87</b>	<b>172.96</b>	<b>250.89</b>
<b>XIX. Paid up Equity Share Capital (face value ₹2 each fully paid) (Refer Note 9)</b>	<b>103.48</b>	<b>55.63</b>	<b>3.08</b>	<b>103.48</b>	<b>3.08</b>	<b>3.08</b>
<b>XX. Other Equity</b>						<b>421.57</b>
<b>XXI. Earning per equity share of ₹2 each* (Refer Note 9)</b>						
<b>A. Earnings Per Share from continuing Operations</b>						
a) Basic (INR)	0.88	1.14	0.55	5.16	3.53	5.11
b) Diluted (INR)	0.88	1.14	0.55	5.16	3.53	5.11
<b>B. Earnings Per Share from discontinuing Operations</b>						
a) Basic (INR)	-	-	(0.11)	(0.13)	(0.19)	(0.31)
b) Diluted (INR)	-	-	(0.11)	(0.13)	(0.19)	(0.31)
<b>C. Earnings Per Share from Continuing Operation and Discontinued Operations:</b>						
a) Basic (INR)	0.88	1.14	0.44	5.03	3.34	4.80
b) Diluted (INR)	0.88	1.14	0.44	5.03	3.34	4.80

\* EPS is not annualized for quarter and nine months ended December 31, 2024, quarter ended September 30, 2024 and quarter and nine months ended December 31, 2023.





**Laxmi Dental Limited (Formerly known as Laxmi Dental Export Private Limited)**

**Notes to Unaudited Consolidated financial results :**

- The unaudited consolidated financial results for the quarter and nine months ended December 31, 2024 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 13, 2025. The Statutory Auditors of the Company have carried out limited review (for the quarter ended December 31, 2024 and year to date ended December 31, 2024) on the above results in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (the Regulation), as amended and expressed an unmodified conclusion.
- The unaudited consolidated financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulation.
- The figures of the corresponding quarter ended and nine month period ended December 31, 2023 and the quarter ended September ended 30, 2024 are presented based on the information compiled by the management in accordance with IND AS and have not been subject to review or audit by the statutory auditors. However, the management have prepared the results for the said periods by applying consistent accounting policies. The requirement of submission of quarterly unaudited standalone financial results is applicable on the listing of the equity shares of the company for the quarter ended December 31, 2024. Accordingly, these financial results have been prepared for the first time in compliance with the regulations.
- The figures for the year ended March 31, 2024 have been extracted from the general purpose consolidated financial statements of the company which were audited by the Statutory Auditors of the company.

**5 Consolidated Segment wise Revenue, Results, Assets and Liabilities.**

The Chief Operational Decision Maker (CODM) monitors the operating results of its Business Segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on profit or loss and is measured consistently with profit or loss in the financial statements. Operating segments have been identified on the basis of the nature of products / services and have been identified as per the quantitative criteria specified in the Ind AS 108 which are described below:-  
**Laboratory Business :** This segment comprises of Dental Prosthesis such as metal free crowns & bridges, Porcelain Fused to Metal ("PFM") Crowns and Bridges Dentures.  
**Aligners Business :** This segment comprises of Dental Aligners, Retainers, Raw Materials for Aligners, Sport Guards, Night Guards, Sleep Apnea Devices.  
**Other Business :** This segment comprises of Dental distribution products used in Dental Laboratory, Dental Clinical Services and Dental Educational Courses.

	Quarter ended			Nine months ended		Year ended 31-Mar-24
	31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	
	Unaudited	(Unaudited) Refer Note 3	(Unaudited) Refer Note 3	Unaudited	(Unaudited) Refer Note 3	
<b>Segment revenue (Including inter-segment revenue)</b>						
Laboratory Business	393.96	360.65	339.10	1,157.18	960.54	1,299.56
Aligners Business	226.65	207.33	143.55	616.33	381.05	567.57
Other Business	32.45	34.27	29.66	102.09	108.02	168.29
<b>Total</b>	<b>653.06</b>	<b>602.25</b>	<b>512.31</b>	<b>1,875.60</b>	<b>1,449.61</b>	<b>2,035.42</b>
Less: Inter-segment revenue	(36.46)	(31.06)	(34.45)	(91.20)	(64.53)	(99.87)
<b>Total Revenue from Operations</b>	<b>616.60</b>	<b>571.19</b>	<b>477.86</b>	<b>1,784.40</b>	<b>1,385.08</b>	<b>1,935.55</b>
<b>Segment results</b>						
Laboratory Business	53.52	44.60	0.01	178.99	23.18	113.12
Aligners Business	38.35	43.00	38.55	134.84	92.30	119.77
Other Business	4.27	(0.34)	0.70	9.67	5.59	5.01
<b>Total</b>	<b>96.14</b>	<b>87.26</b>	<b>39.26</b>	<b>323.50</b>	<b>121.07</b>	<b>237.90</b>
Add: Other income	5.86	7.27	2.03	17.07	14.04	17.09
Less: Depreciation and amortisation	(39.53)	(34.01)	(32.46)	(107.21)	(86.78)	(119.36)
Less: Finance costs	(15.35)	(11.75)	(13.33)	(41.33)	(35.51)	(49.54)
<b>Profit/ (Loss) before exceptional item and tax</b>	<b>47.12</b>	<b>48.77</b>	<b>(4.50)</b>	<b>192.03</b>	<b>12.82</b>	<b>86.09</b>
Exceptional item (refer note 8)	-	-	-	66.17	-	(0.85)
<b>Profit/ (Loss) before tax</b>	<b>47.12</b>	<b>48.77</b>	<b>(4.50)</b>	<b>258.20</b>	<b>12.82</b>	<b>85.24</b>
Less: Tax expense/(credit)	(10.70)	(11.38)	14.09	(39.76)	104.99	94.17
Add: Share in profit after tax of joint venture (net)	11.75	21.56	19.52	64.26	67.03	88.88
<b>Net profit for the period from continuing operations</b>	<b>48.17</b>	<b>58.95</b>	<b>29.11</b>	<b>282.70</b>	<b>184.84</b>	<b>268.29</b>
Profit/ (Loss) after Tax from discontinued operations	-	-	(5.61)	(7.09)	(9.59)	(16.00)
<b>Profit for the period/ year</b>	<b>48.17</b>	<b>58.95</b>	<b>23.50</b>	<b>275.61</b>	<b>175.25</b>	<b>252.29</b>

**Segment assets and liabilities:** The CODM does not monitor operating assets used by the operating segment. Therefore, disclosures of segment assets, liabilities and capital expenditure have not been given.

- During the quarter, the Board of Directors and Shareholders of the Company has approved the Employee Stock Option Plan 2024 ("ESOP 2024") for the employees of the Company and its subsidiary companies comprising of equity shares of the Company, not exceeding 5,00,000 equity shares of face value of Rs. 2/- each from which the total number of options granted was 351,672 equity shares of face value of Rs. 2/- each on December 14, 2024.
- During the quarter ended December 31, 2024, the Company has converted the 0.0001% Compulsorily Convertible Preference Shares (CCPS) aggregating to 290,597 preference shares of par value of Rs. 400 each converted to 23,930,663 Equity Shares of Rs. 2 each.
- On May 07, 2024, the Company sold one of its Investment properties at the sale consideration of Rs. 101 million. The book value of the aforesaid Property as on the date of sale was Rs. 7.10 million. The Company accounted for difference between the sale consideration and book value as gain on sale of Investment property Rs. 66.17 million (net of tax Rs. 27.73 million) as an exceptional gain. During the previous year, the group has recognised the loss of Rs. 0.85 millions as an exceptional items on dissolution of subsidiary Techlab Consulting LLP.
- During the period ended December 31, 2024, the Company split its 309,060 equity shares of face value of Rs.10 each to 1,545,300 Equity Shares of face value of Rs.2 each. Further, on approval of the Board of Directors and Shareholders, the company issued 26,270,100 bonus shares (17:1) face value of Rs. 2 each, by capitalizing the free reserves. Basic and Diluted EPS disclosed after considering effect of bonus and split equity shares issued.
- Subsequent to the quarter and nine month ended December 31, 2024, the Company has completed an Initial Public Offer of 16,309,766 equity shares of face value of Rs. 2/- each comprising of (i) fresh issue of 3,224,299 equity shares at an issue price of Rs. 428 per equity share aggregating to Rs. 1,380 million, and (ii) an offer for sale of 13,085,467 equity shares at an issue price of Rs. 428 per equity share aggregating to Rs. 5,600.58 million and listed on both Bombay Stock Exchange Limited (BSE) and National Stock Exchange (NSE) on January 20, 2025.
- The above unaudited consolidated financial results of the Company are available on the Company's website ([www.laxmidentallimited.com/](http://www.laxmidentallimited.com/)) and stock exchanges websites, BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)), where the shares of the Company are listed.

Date : February 13, 2025  
Place : Mumbai  
[www.laxmidentallimited.com](http://www.laxmidentallimited.com)



  
Sameer Merchant  
CEO & Managing Director  
DIN: 00679893

